Silexion Therapeutics Ltd.

SLXN

NASDAQ

Healthcare

Biotechnology

Jerusalem, IL11 employeessilexion.com

$1.18

-0.04(-3.28%)

Mkt Cap $661.9K

$1.16

$15.60

52-Week Range

At a Glance

AI-generated

8-K

Silexion Therapeutics Corp's Board of Directors removed Ilan Levin from his position as a member of the Board, effective immediately on March 25, 2026. The removal was effected via a unanimous written determination by all other Board members pursuant to Article 28.7 of the Company’s Amended and Restated Articles of Association.

$661.9K

Market Cap

—

Revenue

-$2M

Net Income

Employees11

Fundamentals

How The Business Makes Money

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.

Industry Biotechnology

Activity

What Changed Recently

Management Change

Mar 24, 2026

. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers (b) Removal

Regulation FD

Mar 23, 2026

of this Form 8-K, including the information in the press release, shall not be deemed to be incorporated by reference in the filings of the registrant under the

Regulation FD

Feb 2, 2026

of this Form 8-K, including the presentation , shall not be deemed to be incorporated by reference in the filings of the registrant under the Securities Act of

Regulation FD

Jan 5, 2026

of this Form 8-K, including the information in the press release, shall not be deemed to be incorporated by reference in the filings of the registrant under the

Company Profile

CIK0002022416

ISINKYG1281K1307

CUSIPG1281K130

Phone972 2 674 3430

AddressThe Goldyne Savad Institute of Gene Therapy, Jerusalem, 9112001, IL

SEC EDGAR